Drug company officials were a no-show at Tuesday's Senate hearing on drug prices, and they weren't on the witness list for a House Oversight hearing. In rejecting an invitation to testify before the Senate Finance Committee, they yielded the microphone to patients and policy experts and denied themselves a seat at the table in what proved to be a productive, even-handed discussion of the drivers of prescription drug prices and ways to realign government reimbursement schemes and do away with perverse incentives.